These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2759166)

  • 1. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group.
    Wils J; Bleiberg H; Buyse M; Wagener DT; Splinter T; Veenhof C; Herben M; Duez N
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1119-20. PubMed ID: 2759166
    [No Abstract]   [Full Text] [Related]  

  • 2. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas.
    Wils J; Bleiberg H; Dalesio O; Duez N; Blijham G; Planting A; Splinter T; Weber W
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):1017-8. PubMed ID: 3478197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas.
    Wils J; Bleiberg H; Blijham G; Dalesio O; Duez N; Lacave A; Splinter T
    Eur J Cancer Clin Oncol; 1985 Feb; 21(2):191-4. PubMed ID: 3857181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group.
    Abad A; Masuti B; Camps C; Font A; Balañá C; Vicent JM; Sánchez JJ
    Eur J Cancer; 1994; 30A(7):1043. PubMed ID: 7946573
    [No Abstract]   [Full Text] [Related]  

  • 5. Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma.
    Di Bartolomeo M; Zampino MG; Di Leo A; Bajetta E
    Eur J Cancer; 1993; 29A(8):1215-6. PubMed ID: 8518036
    [No Abstract]   [Full Text] [Related]  

  • 6. Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.
    Loehrer PJ; Williams SD; Nichols CR
    Cancer Treat Rep; 1987 Nov; 71(11):1115-6. PubMed ID: 3119208
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Scheithauer W; Kornek G; Raderer M; Koperna-Mach K; Müller C; Karner J; Kastner J; Tetzner C
    J Cancer Res Clin Oncol; 1995; 121 Suppl 3():R7-10. PubMed ID: 8698741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas.
    Topham C; Glees J; Coombes RC
    Oncology; 1993 Apr; 50 Suppl 1():78-80. PubMed ID: 8483561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer.
    Gridelli C; Rossi A; Incoronato P; Bruni GS; Scognamiglio F; Ruffolo P; Rinaldi L; Bianco AR
    Cancer Chemother Pharmacol; 1996; 37(6):613-5. PubMed ID: 8612318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor in patients with advanced pancreatic adenocarcinoma.
    Kornek G; Raderer M; Schenk T; Pidlich J; Schulz F; Globits S; Tetzner C; Scheithauer W
    Cancer; 1995 Oct; 76(8):1356-62. PubMed ID: 8620409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
    Langenbuch T; Mross K; Jonat W; Hossfeld DK
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S93-6. PubMed ID: 2347058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of epirubicin in patients with advanced adenocarcinoma of the pancreas.
    Aoki K; Shimada Y; Okazaki N; Tajiri H; Nose H; Okada S; Shirao K; Yokota T; Yoshida S; Saitoh D
    Eur J Cancer; 1992; 28A(8-9):1590. PubMed ID: 1515280
    [No Abstract]   [Full Text] [Related]  

  • 13. Pancreatoblastoma: response to chemotherapy.
    Vannier JP; Flamant F; Hemet J; Caillaud JM; Gruner M; Bachy B; Lefur R; Lemerle J; Tron P
    Med Pediatr Oncol; 1991; 19(3):187-91. PubMed ID: 1708850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study.
    Magri MD; Foladore S; Veronesi A; Serra C; Nicotra M; Tommasi M; Grandi G; Monfardini S; Bianchi C
    Ann Oncol; 1992 Mar; 3(3):237-8. PubMed ID: 1586623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids.
    Recchia F; Sica G; Casucci D; Rea S; Gulino A; Frati L
    Am J Clin Oncol; 1998 Jun; 21(3):275-8. PubMed ID: 9626797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-acetylcysteine and ifosfamide in the treatment of unresectable pancreatic adenocarcinoma and refractory testicular cancer.
    Loehrer PJ; Williams SD; Einhorn LH
    Semin Oncol; 1983 Mar; 10(1 Suppl 1):72-5. PubMed ID: 6836331
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
    Evans TR; Lofts FJ; Mansi JL; Glees JP; Dalgleish AG; Knight MJ
    Br J Cancer; 1996 May; 73(10):1260-4. PubMed ID: 8630289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, epirubicin, and ifosfamide versus cisplatin, epirubicin, and cyclophosphamide in clear cell carcinoma of the ovary.
    Nishida T; Sugiyama T; Yakushiji M
    Gynecol Oncol; 1997 Nov; 67(2):230. PubMed ID: 9367714
    [No Abstract]   [Full Text] [Related]  

  • 19. Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
    Wagener DJ; Hoogenraad WJ; Rougier P; Lusinchi A; Taal BG; Veenhof CH; de Graeff A; Conroy T; Curran D; Sahmoud T; Wils J
    Eur J Cancer; 1996 Jul; 32A(8):1310-3. PubMed ID: 8869091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
    Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.